Two international academic journals have found that it is effective to apply classical treatments to patients with advanced liver cancer who are not effective even in the latest immune anticancer ...

Last week, BMS announced that the Opdivo plus Yervoy regimen received FDA approval as a first-line treatment for adult and pediatric patients aged 12 years and older with previously untreated, ...

Here is a recap of every FDA approval announced by the regulatory agency in the month of April, spanning various cancer types ...

DelveInsight's Hepatocellular Carcinoma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for Hepatocellular Carcinoma treatment.

A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...

SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, today announced late-breaking clinical data from ...

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and ...

as a first-line treatment for adults with unresectable or metastatic hepatocellular carcinoma (HCC). Median overall survival, the primary outcome measure, was 23.7 months in those randomized to ...

LIVER CANCER, the third leading cause of cancer-related deaths globally, is primarily attributed to hepatocellular carcinoma ...